<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35563214</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1422-0067</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>27</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">4824</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms23094824</ELocationID>
        <Abstract>
          <AbstractText>Gene therapy is a revolutionary, cutting-edge approach to permanently ameliorate or amend many neuromuscular diseases by targeting their genetic origins. Motor neuron diseases and muscular dystrophies, whose genetic causes are well known, are the frontiers of this research revolution. Several genetic treatments, with diverse mechanisms of action and delivery methods, have been approved during the past decade and have demonstrated remarkable results. However, despite the high number of genetic treatments studied preclinically, those that have been advanced to clinical trials are significantly fewer. The most clinically advanced treatments include adeno-associated virus gene replacement therapy, antisense oligonucleotides, and RNA interference. This review provides a comprehensive overview of the advanced gene therapies for motor neuron diseases (i.e., amyotrophic lateral sclerosis and spinal muscular atrophy) and muscular dystrophies (i.e., Duchenne muscular dystrophy, limb-girdle muscular dystrophy, and myotonic dystrophy) tested in clinical trials. Emphasis has been placed on those methods that are a few steps away from their authoritative approval.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chamakioti</LastName>
            <ForeName>Myrsini</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-0065-259X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, School of Medicine, University of Patras, 26504 Patras, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Karantzelis</LastName>
            <ForeName>Nikolaos</ForeName>
            <Initials>N</Initials>
            <Identifier Source="ORCID">0000-0002-6582-6757</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, School of Medicine, University of Patras, 26504 Patras, Greece.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, 79106 Freiburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Taraviras</LastName>
            <ForeName>Stavros</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, School of Medicine, University of Patras, 26504 Patras, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009134" MajorTopicYN="Y">Muscular Atrophy, Spinal</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020388" MajorTopicYN="Y">Muscular Dystrophy, Duchenne</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">gene-targeting therapy</Keyword>
        <Keyword MajorTopicYN="N">motor neuron disorders</Keyword>
        <Keyword MajorTopicYN="N">muscular dystrophies</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>1</Hour>
          <Minute>4</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35563214</ArticleId>
        <ArticleId IdType="pmc">PMC9101723</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms23094824</ArticleId>
        <ArticleId IdType="pii">ijms23094824</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Verma I.M., Somia N. Gene therapy-promises, problems and prospects. Nature. 1997;389:239–242. doi: 10.1038/38410.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/38410</ArticleId>
            <ArticleId IdType="pubmed">9305836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen W., Hu Y., Ju D. Gene therapy for neurodegenerative disorders: Advances, insights and prospects. Acta Pharm. Sin. B. 2020;10:1347–1359. doi: 10.1016/j.apsb.2020.01.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.apsb.2020.01.015</ArticleId>
            <ArticleId IdType="pmc">PMC7488363</ArticleId>
            <ArticleId IdType="pubmed">32963936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aguti S., Malerba A., Zhou H. The progress of AAV-mediated gene therapy in neuromuscular disorders. Expert Opin. Biol. Ther. 2018;18:681–693. doi: 10.1080/14712598.2018.1479739.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14712598.2018.1479739</ArticleId>
            <ArticleId IdType="pubmed">29781327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adachi K., Enoki T., Kawano Y., Veraz M., Nakai H. Drawing a high-resolution functional map of adeno-associated virus capsid by massively parallel sequencing. Nat. Commun. 2014;5:3075. doi: 10.1038/ncomms4075.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms4075</ArticleId>
            <ArticleId IdType="pmc">PMC3941020</ArticleId>
            <ArticleId IdType="pubmed">24435020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albright B.H., Storey C.M., Murlidharan G., Rivera R.M.C., Berry G.E., Madigan V.J., Asokan A. Mapping the Structural Determinants Required for AAVrh.10 Transport across the Blood-Brain Barrier. Mol. Ther. 2018;26:510–523. doi: 10.1016/j.ymthe.2017.10.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ymthe.2017.10.017</ArticleId>
            <ArticleId IdType="pmc">PMC5835146</ArticleId>
            <ArticleId IdType="pubmed">29175157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duque S., Joussemet B., Riviere C., Marais T., Dubreil L., Douar A.-M., Fyfe J., Moullier P., Colle M.-A., Barkats M. Intravenous Administration of Self-complementary AAV9 Enables Transgene Delivery to Adult Motor Neurons. Mol. Ther. 2009;17:1187–1196. doi: 10.1038/mt.2009.71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mt.2009.71</ArticleId>
            <ArticleId IdType="pmc">PMC2835208</ArticleId>
            <ArticleId IdType="pubmed">19367261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rafii M.S., Tuszynski M.H., Thomas R.G., Barba D., Brewer J.B., Rissman R.A., Siffert J., Aisen P.S., Mintzer J., Lerner A., et al.  Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol. 2018;75:834–841. doi: 10.1001/jamaneurol.2018.0233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2018.0233</ArticleId>
            <ArticleId IdType="pmc">PMC5885277</ArticleId>
            <ArticleId IdType="pubmed">29582053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Au H.K.E., Isalan M., Mielcarek M. Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings. Front. Med. 2022;8:809118. doi: 10.3389/fmed.2021.809118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmed.2021.809118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin H., Kanasty R.L., Eltoukhy A.A., Vegas A.J., Dorkin J.R., Anderson D.G. Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 2014;15:541–555. doi: 10.1038/nrg3763.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrg3763</ArticleId>
            <ArticleId IdType="pubmed">25022906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kole R., Krainer A., Altman S. RNA therapeutics: Beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Discov. 2012;11:125–140. doi: 10.1038/nrd3625.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrd3625</ArticleId>
            <ArticleId IdType="pmc">PMC4743652</ArticleId>
            <ArticleId IdType="pubmed">22262036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glazier D.A., Liao J., Roberts B.L., Li X., Yang K., Stevens C.M., Tang W. Chemical Synthesis and Biological Application of Modified Oligonucleotides. Bioconjugate Chem. 2020;31:1213–1233. doi: 10.1021/acs.bioconjchem.0c00060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.bioconjchem.0c00060</ArticleId>
            <ArticleId IdType="pubmed">32227878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iwamoto N., Butler D.C.D., Svrzikapa N., Mohapatra S., Zlatev I., Sah D.W.Y., Meena , Standley S.M., Lu G., Apponi L.H., et al.  Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides. Nat. Biotechnol. 2017;35:845–851. doi: 10.1038/nbt.3948.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt.3948</ArticleId>
            <ArticleId IdType="pubmed">28829437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Østergaard M.E., De Hoyos C.L., Wan W.B., Shen W., Low A., Berdeja A., Vasquez G., Murray S., Migawa M.T., Liang X.-H., et al.  Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides. Nucleic Acids Res. 2020;48:1691–1700. doi: 10.1093/nar/gkaa031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkaa031</ArticleId>
            <ArticleId IdType="pmc">PMC7038945</ArticleId>
            <ArticleId IdType="pubmed">31980820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lundin K.E., Gissberg O., Smith C.I.E., Zain R. Chemical Development of Therapeutic Oligonucleotides. Methods Mol. Biol. 2019;2036:3–16. doi: 10.1007/978-1-4939-9670-4_1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-9670-4_1</ArticleId>
            <ArticleId IdType="pubmed">31410788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quemener A.M., Bachelot L., Forestier A., Donnou-Fournet E., Gilot D., Galibert M.-D. The powerful world of anti-sense oligonucleotides: From bench to bedside. Wiley Interdiscip. Rev. RNA. 2020;11:e1594. doi: 10.1002/wrna.1594.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/wrna.1594</ArticleId>
            <ArticleId IdType="pubmed">32233021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caplen N.J., Parrish S., Imani F., Fire A., Morgan R.A. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl. Acad. Sci. USA. 2001;98:9742–9747. doi: 10.1073/pnas.171251798.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.171251798</ArticleId>
            <ArticleId IdType="pmc">PMC55523</ArticleId>
            <ArticleId IdType="pubmed">11481446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494–498. doi: 10.1038/35078107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/35078107</ArticleId>
            <ArticleId IdType="pubmed">11373684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anastasiadou E., Jacob L.S., Slack F.J. Non-coding RNA networks in cancer. Nat. Rev. Cancer. 2018;18:5–18. doi: 10.1038/nrc.2017.99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc.2017.99</ArticleId>
            <ArticleId IdType="pmc">PMC6337726</ArticleId>
            <ArticleId IdType="pubmed">29170536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rogers S. Shope papilloma virus: A Passenger in man and its significance to the potential control of the host genome. Nature. 1966;212:1220–1222. doi: 10.1038/2121220a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/2121220a0</ArticleId>
            <ArticleId IdType="pubmed">21090446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matranga C., Tomari Y., Shin C., Bartel D.P., Zamore P.D. Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell. 2005;123:607–620. doi: 10.1016/j.cell.2005.08.044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2005.08.044</ArticleId>
            <ArticleId IdType="pubmed">16271386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J.A., Charpentier E. A Programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816–821. doi: 10.1126/science.1225829.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1225829</ArticleId>
            <ArticleId IdType="pmc">PMC6286148</ArticleId>
            <ArticleId IdType="pubmed">22745249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cong L., Ran F.A., Cox D., Lin S., Barretto R., Habib N., Hsu P.D., Wu X., Jiang W., Marraffini L.A., et al.  Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339:819–823. doi: 10.1126/science.1231143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1231143</ArticleId>
            <ArticleId IdType="pmc">PMC3795411</ArticleId>
            <ArticleId IdType="pubmed">23287718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frangoul H., Bobruff Y., Cappellini M.D., Corbacioglu S., Fernandez R.C.M., De La Fuente J., Grupp S.A., Handgretinger R., Ho T.W., Imren S., et al.  Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells. Blood. 2020;136:3–4. doi: 10.1182/blood-2020-139575.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2020-139575</ArticleId>
            <ArticleId IdType="pubmed">32614960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosell R., Filipska M., Chaib I., Lligé D., Laguia F. Commentary: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Front. Oncol. 2020;10:1726. doi: 10.3389/fonc.2020.01726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2020.01726</ArticleId>
            <ArticleId IdType="pmc">PMC7511626</ArticleId>
            <ArticleId IdType="pubmed">33014853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mullard A. First in vivo CRISPR candidate enters the clinic. Nat. Rev. Drug Discov. 2019;18:656. doi: 10.1038/d41573-019-00139-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/d41573-019-00139-z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gillmore J.D., Gane E., Taubel J., Kao J., Fontana M., Maitland M.L., Seitzer J., O’Connell D., Walsh K.R., Wood K., et al.  CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N. Engl. J. Med. 2021;385:493–502. doi: 10.1056/NEJMoa2107454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2107454</ArticleId>
            <ArticleId IdType="pubmed">34215024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nelson C.E., Robinson-Hamm J.N., Gersbach C.A. Genome engineering: A new approach to gene therapy for neuromuscular disorders. Nat. Rev. Neurol. 2017;13:647–661. doi: 10.1038/nrneurol.2017.126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrneurol.2017.126</ArticleId>
            <ArticleId IdType="pubmed">28960187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nathwani A.C., Tuddenham E.G., Rangarajan S., Rosales C., McIntosh J., Linch D.C., Chowdary P., Riddell A., Pie A.J., Harrington C., et al.  Adenovirus-associated virus vector–mediated gene transfer in hemophilia B. N. Engl. J. Med. 2011;365:2357–2365. doi: 10.1056/NEJMoa1108046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1108046</ArticleId>
            <ArticleId IdType="pmc">PMC3265081</ArticleId>
            <ArticleId IdType="pubmed">22149959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan Z., McCray P.B., Jr., Engelhardt J.F. Advances in gene therapy for cystic fibrosis lung disease. Hum. Mol. Genet. 2019;28:R88–R94. doi: 10.1093/hmg/ddz139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddz139</ArticleId>
            <ArticleId IdType="pmc">PMC6796993</ArticleId>
            <ArticleId IdType="pubmed">31332440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anastasiadou E., Seto A.G., Beatty X., Hermreck M., Gilles M.-E., Stroopinsky D., Pinter-Brown L.C., Pestano L., Marchese C., Avigan D., et al.  Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo. Clin. Cancer Res. 2021;27:1139–1149. doi: 10.1158/1078-0432.CCR-20-3139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-20-3139</ArticleId>
            <ArticleId IdType="pmc">PMC8287597</ArticleId>
            <ArticleId IdType="pubmed">33208342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gilboa E., Smith C. Gene therapy for infectious diseases: The AIDS model. Trends Genet. 1994;10:139–144. doi: 10.1016/0168-9525(94)90216-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0168-9525(94)90216-X</ArticleId>
            <ArticleId IdType="pubmed">7913251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duan D., Goemans N., Takeda S., Mercuri E., Aartsma-Rus A. Duchenne muscular dystrophy. Nat. Rev. Dis. Primers. 2021;7:13. doi: 10.1038/s41572-021-00248-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41572-021-00248-3</ArticleId>
            <ArticleId IdType="pubmed">33602943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abe K., Itoyama Y., Sobue G., Tsuji S., Aoki M., Doyu M., Hamada C., Kondo K., Yoneoka T., Akimoto M., et al.  Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph. Lateral Scler. Front. Degener. 2014;15:610–617. doi: 10.3109/21678421.2014.959024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/21678421.2014.959024</ArticleId>
            <ArticleId IdType="pmc">PMC4266079</ArticleId>
            <ArticleId IdType="pubmed">25286015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Writing Group on behalf of the Edaravone (MCI-186) ALS 17 Study Group  Exploratory double-blind, par-allel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2017;18:20–31. doi: 10.1080/21678421.2017.1362000.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/21678421.2017.1362000</ArticleId>
            <ArticleId IdType="pubmed">28872918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshino H., Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study) Amyotroph. Lateral Scler. 2006;7:247–251. doi: 10.1080/17482960600881870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/17482960600881870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bensimon G., Lacomblez L., Meininger V., The ALS/Riluzole Study Group  A controlled trial of riluzole in amyotrophic Lateral sclerosis. N. Engl. J. Med. 1994;330:585–591. doi: 10.1056/NEJM199403033300901.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId>
            <ArticleId IdType="pubmed">8302340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bellingham M.C. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: What have we learned in the last decade? CNS Neurosci. Ther. 2011;17:4–31. doi: 10.1111/j.1755-5949.2009.00116.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1755-5949.2009.00116.x</ArticleId>
            <ArticleId IdType="pmc">PMC6493865</ArticleId>
            <ArticleId IdType="pubmed">20236142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoy S.M. Nusinersen: First Global Approval. Drugs. 2017;77:473–479. doi: 10.1007/s40265-017-0711-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40265-017-0711-7</ArticleId>
            <ArticleId IdType="pubmed">28229309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Vivo D.C., Bertini E., Swoboda K., Hwu W.-L., Crawford T.O., Finkel R.S., Kirschner J., Kuntz N.L., Parsons J.A., Ryan M.M., et al.  Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul. Disord. 2019;29:842–856. doi: 10.1016/j.nmd.2019.09.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2019.09.007</ArticleId>
            <ArticleId IdType="pmc">PMC7127286</ArticleId>
            <ArticleId IdType="pubmed">31704158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aartsma-Rus A., Krieg A.M. FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga. Nucleic Acid Ther. 2017;27:1–3. doi: 10.1089/nat.2016.0657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/nat.2016.0657</ArticleId>
            <ArticleId IdType="pmc">PMC5312460</ArticleId>
            <ArticleId IdType="pubmed">27929755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heo Y.A. Golodirsen: First Approval. Drugs. 2020;80:329–333. doi: 10.1007/s40265-020-01267-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40265-020-01267-2</ArticleId>
            <ArticleId IdType="pubmed">32026421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shirley M. Casimersen: First Approval. Drugs. 2021;81:875–879. doi: 10.1007/s40265-021-01512-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40265-021-01512-2</ArticleId>
            <ArticleId IdType="pubmed">33861387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dhillon S. Viltolarsen: First Approval. Drugs. 2020;80:1027–1031. doi: 10.1007/s40265-020-01339-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40265-020-01339-3</ArticleId>
            <ArticleId IdType="pubmed">32519222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hardiman O., Al-Chalabi A., Chio A., Corr E.M., Logroscino G., Robberecht W., Shaw P.J., Simmons Z., van den Berg L.H. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Primers. 2017;3:17071. doi: 10.1038/nrdp.2017.71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId>
            <ArticleId IdType="pubmed">28980624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wijesekera L.C., Nigel Leigh P. Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009;4:3. doi: 10.1186/1750-1172-4-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1750-1172-4-3</ArticleId>
            <ArticleId IdType="pmc">PMC2656493</ArticleId>
            <ArticleId IdType="pubmed">19192301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phukan J., Pender N., Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol. 2007;6:994–1003. doi: 10.1016/S1474-4422(07)70265-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(07)70265-X</ArticleId>
            <ArticleId IdType="pubmed">17945153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Chalabi A., Hardiman O. The epidemiology of ALS: A conspiracy of genes, environment and time. Nat. Rev. Neurol. 2013;9:617–628. doi: 10.1038/nrneurol.2013.203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrneurol.2013.203</ArticleId>
            <ArticleId IdType="pubmed">24126629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amado D.A., Davidson B.L. Gene therapy for ALS: A review. Mol. Ther. 2021;29:3345–3358. doi: 10.1016/j.ymthe.2021.04.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ymthe.2021.04.008</ArticleId>
            <ArticleId IdType="pmc">PMC8636154</ArticleId>
            <ArticleId IdType="pubmed">33839324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pyun W.-B., Hahn W., Kim D.-S., Yoo W.-S., Lee S.-D., Won J.-H., Rho B.-S., Park Z.-Y., Kim J.-M., Kim S. Naked DNA expressing two isoforms of hepatocyte growth factor induces collateral artery augmentation in a rabbit model of limb ischemia. Gene Ther. 2010;17:1442–1452. doi: 10.1038/gt.2010.101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/gt.2010.101</ArticleId>
            <ArticleId IdType="pubmed">20668482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taniyama Y., Morishita R., Hiraoka K., Aoki M., Nakagami H., Yamasaki K., Matsumoto K., Nakamura T., Kaneda Y., Ogihara T. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb Ischemia model. Circulation. 2001;104:2344–2350. doi: 10.1161/hc4401.098470.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/hc4401.098470</ArticleId>
            <ArticleId IdType="pubmed">11696476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng C., Guo G.F., Martinez J.A., Singh V., Zochodne D.W. Dynamic plasticity of axons within a cutaneous milieu. J. Neurosci. 2010;30:14735–14744. doi: 10.1523/JNEUROSCI.2919-10.2010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.2919-10.2010</ArticleId>
            <ArticleId IdType="pmc">PMC6633624</ArticleId>
            <ArticleId IdType="pubmed">21048132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ebens A., Brose K., Leonardo E.D., Hanson M.G., Jr., Bladt F., Birchmeier C., Barres B.A., Tessier-Lavigne M. Hepatocyte Growth Factor/Scatter Factor Is an Axonal Chemoattractant and a Neurotrophic Factor for Spinal Motor Neurons. Neuron. 1996;17:1157–1172. doi: 10.1016/S0896-6273(00)80247-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0896-6273(00)80247-0</ArticleId>
            <ArticleId IdType="pubmed">8982163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Funakoshi H., Nakamura T. Identification of HGF-like protein as a novel neurotrophic factor for avian dorsal root ganglion sensory neurons. Biochem. Biophys. Res. Commun. 2001;283:606–612. doi: 10.1006/bbrc.2001.4819.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/bbrc.2001.4819</ArticleId>
            <ArticleId IdType="pubmed">11341767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gascon E., Gaillard S., Malapert P., Liu Y., Rodat-Despoix L., Samokhvalov I.M., Delmas P., Helmbacher F., Maina F., Moqrich A. Hepatocyte growth factor-met signaling is required for Runx1 extinction and peptidergic differentiation in Primary nociceptive neurons. J. Neurosci. 2010;30:12414–12423. doi: 10.1523/JNEUROSCI.3135-10.2010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.3135-10.2010</ArticleId>
            <ArticleId IdType="pmc">PMC6633456</ArticleId>
            <ArticleId IdType="pubmed">20844136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hashimoto N., Yamanaka H., Fukuoka T., Dai Y., Obata K., Mashimo T., Noguchi K. Expression of HGF and cMet in the peripheral nervous system of adult rats following sciatic nerve injury. NeuroReport. 2001;12:1403–1407. doi: 10.1097/00001756-200105250-00022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00001756-200105250-00022</ArticleId>
            <ArticleId IdType="pubmed">11388419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kato N., Nemoto K., Nakanishi K., Morishita R., Kaneda Y., Uenoyama M., Ikeda T., Fujikawa K. Nonviral HVJ (hemagglutinating virus of Japan) liposome-mediated retrograde gene transfer of human hepatocyte growth factor into rat nervous system promotes functional and histological recovery of the crushed nerve. Neurosci. Res. 2005;52:299–310. doi: 10.1016/j.neures.2005.04.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neures.2005.04.004</ArticleId>
            <ArticleId IdType="pubmed">15878632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ko K.R., Lee J., Lee D., Nho B., Kim S. Hepatocyte Growth Factor (HGF) Promotes Peripheral Nerve Regeneration by Activating Repair Schwann Cells. Sci. Rep. 2018;8:8316. doi: 10.1038/s41598-018-26704-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-018-26704-x</ArticleId>
            <ArticleId IdType="pmc">PMC5973939</ArticleId>
            <ArticleId IdType="pubmed">29844434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maina F., Hilton M.C., Ponzetto C., Davies A.M., Klein R. Met receptor signaling is required for sensory nerve development and HGF promotes axonal growth and survival of sensory neurons. Genes Dev. 1997;11:3341–3350. doi: 10.1101/gad.11.24.3341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.11.24.3341</ArticleId>
            <ArticleId IdType="pmc">PMC316818</ArticleId>
            <ArticleId IdType="pubmed">9407027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong V., Glass D.J., Arriaga R., Yancopoulos G.D., Lindsay R.M., Conn G. Hepatocyte growth factor promotes motor neuron survival and synergizes with ciliary neurotrophic factor. J. Biol. Chem. 1997;272:5187–5191. doi: 10.1074/jbc.272.8.5187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.272.8.5187</ArticleId>
            <ArticleId IdType="pubmed">9030587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang X.-M., Toma J.G., Bamji S.X., Belliveau D.J., Kohn J., Park M., Miller F.D. Autocrine hepatocyte growth factor provides a local mechanism for promoting axonal growth. J. Neurosci. 1998;18:8369–8381. doi: 10.1523/JNEUROSCI.18-20-08369.1998.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.18-20-08369.1998</ArticleId>
            <ArticleId IdType="pmc">PMC6792841</ArticleId>
            <ArticleId IdType="pubmed">9763480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kessler J.A., Shaibani A., Sang C.N., Christiansen M., Kudrow D., Vinik A., Shin N. Gene therapy for diabetic peripheral neuropathy: A randomized, placebo-controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor. Clin. Transl. Sci. 2021;14:1176–1184. doi: 10.1111/cts.12977.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cts.12977</ArticleId>
            <ArticleId IdType="pmc">PMC8212761</ArticleId>
            <ArticleId IdType="pubmed">33465273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kibbe M.R., Hirsch A.T., Mendelsohn F.O., Davies M.G., Pham H., Saucedo J., Marston W., Pyun W.-B., Min S.-K., Peterson B.G., et al.  Safety and efficacy of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with critical limb ischemia. Gene Ther. 2015;23:306–312. doi: 10.1038/gt.2015.110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/gt.2015.110</ArticleId>
            <ArticleId IdType="pubmed">26649448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Helixmith   [(accessed on 27 March 2022)].  Available online:  https://www.helixmith.com/bbs/board.php?bo_table=s5_1_eng&amp;wr_id=36.</Citation>
        </Reference>
        <Reference>
          <Citation>Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O’Regan J.P., Deng H.-X., et al.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59–62. doi: 10.1038/362059a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/362059a0</ArticleId>
            <ArticleId IdType="pubmed">8446170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pansarasa O., Bordoni M., Diamanti L., Sproviero D., Gagliardi S., Cereda C. SOD1 in Amyotrophic Lateral Sclerosis: “Ambivalent” Behavior Connected to the Disease. Int. J. Mol. Sci. 2018;19:1345.  doi: 10.3390/ijms19051345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms19051345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller T., Pestronk P.A., David W., Rothstein J., Simpson E., Appel S.H., Andres P.L., Mahoney K., Allred P., Alexander K., et al.  A Phase I, Randomised, First-in-Human Study of an Antisense Oligonucleotide Directed Against SOD1 Delivered Intrathecally in SOD1-Familial ALS Patients. Lancet Neurol. 2013;12:435. doi: 10.1016/S1474-4422(13)70061-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(13)70061-9</ArticleId>
            <ArticleId IdType="pmc">PMC3712285</ArticleId>
            <ArticleId IdType="pubmed">23541756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller T., Cudkowicz M., Shaw P.J., Andersen P.M., Atassi N., Bucelli R.C., Genge A., Glass J., Ladha S., Ludolph A.L., et al.  Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 2020;383:109–119. doi: 10.1056/NEJMoa2003715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId>
            <ArticleId IdType="pubmed">32640130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biogen   [(accessed on 27 March 2022)].  Available online:  https://investors.biogen.com/news-releases/news-release-details/biogen-announces-topline-results-tofersen-phase-3-study-and-its.</Citation>
        </Reference>
        <Reference>
          <Citation>Fernandez M., McClain M.E., Martinez R.A., Snow K., Lipe H., Ravits J., Bird T.D., La Spada A.R. Late-onset SCA2: 33 CAG repeats are sufficient to cause disease. Neurology. 2000;55:569–572. doi: 10.1212/WNL.55.4.569.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.55.4.569</ArticleId>
            <ArticleId IdType="pubmed">10953195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang M.-D., Gomes J., Cashman N.R., Little J., Krewski D. Intermediate CAG repeat expansion in the ATXN2 gene is a unique genetic risk factor for ALS−A systematic review and meta-analysis of observational studies. PLoS ONE. 2014;9:e105534.  doi: 10.1371/journal.pone.0105534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105534</ArticleId>
            <ArticleId IdType="pmc">PMC4141758</ArticleId>
            <ArticleId IdType="pubmed">25148523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arai T., Hasegawa M., Akiyama H., Ikeda K., Nonaka T., Mori H., Mann D., Tsuchiya K., Yoshida M., Hashizume Y., et al.  TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006;351:602–611. doi: 10.1016/j.bbrc.2006.10.093.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId>
            <ArticleId IdType="pubmed">17084815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al.  Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130–133. doi: 10.1126/science.1134108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1134108</ArticleId>
            <ArticleId IdType="pubmed">17023659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu-Yesucevitz L., Bilgutay A., Zhang Y.-J., Vanderweyde T., Citro A., Mehta T., Zaarur N., McKee A., Bowser R., Sherman M., et al.  Correction: Tar DNA binding protein-43 (TDP-43) associates with stress granules: Analysis of cultured cells and Pathological brain tissue. PLoS ONE. 2010;5:e13205.  doi: 10.1371/journal.pone.0013250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0013250</ArticleId>
            <ArticleId IdType="pmc">PMC2951895</ArticleId>
            <ArticleId IdType="pubmed">20949028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang K., Daigle J.G., Cunningham K., Coyne A.N., Ruan K., Grima J.C., Bowen K., Wadhwa H., Yang P., Rigo F., et al.  Stress Granule Assembly Disrupts Nucleocytoplasmic Transport. Cell. 2018;173:958–971.e17. doi: 10.1016/j.cell.2018.03.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2018.03.025</ArticleId>
            <ArticleId IdType="pmc">PMC6083872</ArticleId>
            <ArticleId IdType="pubmed">29628143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y.R., King O.D., Shorter J., Gitler A.D. Stress granules as crucibles of ALS pathogenesis. J. Cell Biol. 2013;201:361–372. doi: 10.1083/jcb.201302044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.201302044</ArticleId>
            <ArticleId IdType="pmc">PMC3639398</ArticleId>
            <ArticleId IdType="pubmed">23629963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elden A.C., Kim H.-J., Hart M.P., Chen-Plotkin A.S., Johnson B.S., Fang X., Armakola M., Geser F., Greene R., Lu M.M., et al.  Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069–1075. doi: 10.1038/nature09320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature09320</ArticleId>
            <ArticleId IdType="pmc">PMC2965417</ArticleId>
            <ArticleId IdType="pubmed">20740007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Webster C.P., Smith E.F., Bauer C.S., Moller A., Hautbergue G.M., Ferraiuolo L., Myszczynska M., Higginbottom A., Walsh M.J., Whitworth A.J., et al.  The C9orf72 protein interacts with Rab1a and the ULK 1 complex to regulate initiation of autophagy. EMBO J. 2016;35:1656–1676. doi: 10.15252/embj.201694401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/embj.201694401</ArticleId>
            <ArticleId IdType="pmc">PMC4969571</ArticleId>
            <ArticleId IdType="pubmed">27334615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J., et al.  Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245–256. doi: 10.1016/j.neuron.2011.09.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId>
            <ArticleId IdType="pmc">PMC3202986</ArticleId>
            <ArticleId IdType="pubmed">21944778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Renton A.E., Majounie E., Waite A., Simon-Saánchez J., Rollinson S., Gibbs J.R., Schymick J.C., Laaksovirta H., van Swieten J.C., Myllykangas L., et al.  A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron. 2011;72:257–268. doi: 10.1016/j.neuron.2011.09.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId>
            <ArticleId IdType="pmc">PMC3200438</ArticleId>
            <ArticleId IdType="pubmed">21944779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balendra R., Isaacs A.M. C9orf72-mediated ALS and FTD: Multiple pathways to disease. Nat. Rev. Neurol. 2018;14:544–558. doi: 10.1038/s41582-018-0047-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41582-018-0047-2</ArticleId>
            <ArticleId IdType="pmc">PMC6417666</ArticleId>
            <ArticleId IdType="pubmed">30120348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haeusler A.R., Donnelly C.J., Rothstein J.D. The expanding biology of the C9orf72 nucleotide repeat expansion in neurodegenerative disease. Nat. Rev. Neurosci. 2016;17:383–395. doi: 10.1038/nrn.2016.38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrn.2016.38</ArticleId>
            <ArticleId IdType="pmc">PMC7376590</ArticleId>
            <ArticleId IdType="pubmed">27150398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang J., Zhu Q., Gendron T.F., Saberi S., McAlonis-Downes M., Seelman A., Stauffer J.E., Jafar-Nejad P., Drenner K., Schulte D., et al.  Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs. Neuron. 2016;90:535–550. doi: 10.1016/j.neuron.2016.04.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2016.04.006</ArticleId>
            <ArticleId IdType="pmc">PMC4860075</ArticleId>
            <ArticleId IdType="pubmed">27112497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y., Dodart J.-C., Tran H., Berkovitch S., Braun M., Byrne M., Durbin A.F., Hu X.S., Iwamoto N., Jang H.G., et al.  Variant-selective stereopure oligonucleotides protect against pathologies associated with C9orf72-repeat expansion in preclinical models. Nat. Commun. 2021;12:847. doi: 10.1038/s41467-021-21112-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-021-21112-8</ArticleId>
            <ArticleId IdType="pmc">PMC7870851</ArticleId>
            <ArticleId IdType="pubmed">33558503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y., Andreucci A., Iwamoto N., Yin Y., Yang H., Liu F., Patil S., Mohapatra S., Purcell-Estabrook E., Taborn K., et al.  WVE-004, an investigational stereopure antisense oligonucleotide for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) (2302) Neurology. 2021;96((Suppl. 15)):2302.</Citation>
        </Reference>
        <Reference>
          <Citation>Kwiatkowski T.J., Jr., Bosco D.A., Leclerc A.L., Tamrazian E., Vanderburg C.R., Russ C., Davis A., Gilchrist J., Kasarskis E.J., Munsat T., et al.  Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205–1208. doi: 10.1126/science.1166066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1166066</ArticleId>
            <ArticleId IdType="pubmed">19251627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vance C., Rogelj B., Hortobágyi T., De Vos K.J., Nishimura A.L., Sreedharan J., Hu X., Smith B., Ruddy D., Wright P., et al.  Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208–1211. doi: 10.1126/science.1165942.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1165942</ArticleId>
            <ArticleId IdType="pmc">PMC4516382</ArticleId>
            <ArticleId IdType="pubmed">19251628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ratti A., Buratti E. Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins. J. Neurochem. 2016;138:95–111. doi: 10.1111/jnc.13625.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jnc.13625</ArticleId>
            <ArticleId IdType="pubmed">27015757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mastrocola A.S., Kim S.H., Trinh A.T., Rodenkirch L.A., Tibbetts R.S. The RNA-binding protein fused in sarcoma (FUS) functions downstream of Poly(ADP-ribose) polymerase (PARP) in response to DNA damage. J. Biol. Chem. 2013;288:24731–24741. doi: 10.1074/jbc.M113.497974.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M113.497974</ArticleId>
            <ArticleId IdType="pmc">PMC3750169</ArticleId>
            <ArticleId IdType="pubmed">23833192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hennig S., Kong G., Mannen T., Sadowska A., Kobelke S., Blythe A., Knott G.J., Iyer K.S., Ho D., Newcombe E., et al.  Prion-like domains in RNA binding proteins are essential for building subnuclear paraspeckles. J. Cell Biol. 2015;210:529–539. doi: 10.1083/jcb.201504117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.201504117</ArticleId>
            <ArticleId IdType="pmc">PMC4539981</ArticleId>
            <ArticleId IdType="pubmed">26283796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mejzini R., Flynn L.L., Pitout I.L., Fletcher S., Wilton S.D., Akkari P.A. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front. Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId>
            <ArticleId IdType="pmc">PMC6909825</ArticleId>
            <ArticleId IdType="pubmed">31866818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim G., Gautier O., Tassoni-Tsuchida E., Ma X.R., Gitler A.D. ALS Genetics: Gains, Losses, and Implications for Future Therapies. Neuron. 2020;108:822–842. doi: 10.1016/j.neuron.2020.08.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2020.08.022</ArticleId>
            <ArticleId IdType="pmc">PMC7736125</ArticleId>
            <ArticleId IdType="pubmed">32931756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conte A., Lattante S., Zollino M., Marangi G., Luigetti M., Del Grande A., Servidei S., Trombetta F., Sabatelli M. P525L FUS mutation is consistently associated with a severe form of juvenile Amyotrophic Lateral Sclerosis. Neuromuscul. Disord. 2012;22:73–75. doi: 10.1016/j.nmd.2011.08.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2011.08.003</ArticleId>
            <ArticleId IdType="pubmed">21907581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korobeynikov V.A., Lyashchenko A.K., Blanco-Redondo B., Jafar-Nejad P., Shneider N.A. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat. Med. 2022;28:104–116. doi: 10.1038/s41591-021-01615-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-021-01615-z</ArticleId>
            <ArticleId IdType="pmc">PMC8799464</ArticleId>
            <ArticleId IdType="pubmed">35075293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnold C. Tailored treatment for ALS poised to move ahead. Nat. Med. 2019.  
ahead of print
.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/d41591-019-00013-w</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borel F., Gernoux G., Cardozo B., Metterville J.P., Cabrera G.T., Song L., Su Q., Gao G.P., Elmallah M.K., Brown R.H., et al.  Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1G93A Mice and Nonhuman Primates. Hum. Gene Ther. 2016;27:19–31. doi: 10.1089/hum.2015.122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/hum.2015.122</ArticleId>
            <ArticleId IdType="pmc">PMC4741242</ArticleId>
            <ArticleId IdType="pubmed">26710998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borel F., Gernoux G., Sun H., Stock R., Blackwood M., Brown R.H., Mueller C. Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques. Sci. Transl. Med. 2018;10:eaau6414. doi: 10.1126/scitranslmed.aau6414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aau6414</ArticleId>
            <ArticleId IdType="pubmed">30381409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stoica L., Todeasa S.H., Cabrera G.T., Salameh J.S., ElMallah M.K., Mueller C., Brown R.H., Jr., Sena-Esteves M. Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. Ann. Neurol. 2016;79:687–700. doi: 10.1002/ana.24618.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.24618</ArticleId>
            <ArticleId IdType="pmc">PMC5374859</ArticleId>
            <ArticleId IdType="pubmed">26891182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mueller C., Berry J.D., McKenna-Yasek D.M., Gernoux G., Owegi M.A., Pothier L.M., Douthwright C.L., Gelevski D., Luppino S.D., Blackwood M., et al.  SOD1Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS. N. Engl. J. Med. 2020;383:151–158. doi: 10.1056/NEJMoa2005056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2005056</ArticleId>
            <ArticleId IdType="pubmed">32640133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castro D., Iannaccone S.T. Spinal Muscular Atrophy: Therapeutic Strategies. Curr. Treat. Options Neurol. 2014;16:316. doi: 10.1007/s11940-014-0316-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11940-014-0316-3</ArticleId>
            <ArticleId IdType="pubmed">25245431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farrar M.A., Park S.B., Vucic S., Carey K., Turner B., Gillingwater T., Swoboda K., Kiernan M.C. Emerging therapies and challenges in spinal muscular atrophy. Ann. Neurol. 2017;81:355–368. doi: 10.1002/ana.24864.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.24864</ArticleId>
            <ArticleId IdType="pmc">PMC5396275</ArticleId>
            <ArticleId IdType="pubmed">28026041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lefebvre S., Bürglen L., Reboullet S., Clermont O., Burlet P., Viollet L., Benichou B., Cruaud C., Millasseau P., Zeviani M., et al.  Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80:155–165. doi: 10.1016/0092-8674(95)90460-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0092-8674(95)90460-3</ArticleId>
            <ArticleId IdType="pubmed">7813012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Day J.W., Finkel R.S., Chiriboga C.A., Connolly A.M., Crawford T.O., Darras B.T., Iannaccone S.T., Kuntz N.L., Peña L.D.M., Shieh P.B., et al.  Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): An open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20:284–293. doi: 10.1016/S1474-4422(21)00001-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(21)00001-6</ArticleId>
            <ArticleId IdType="pubmed">33743238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mendell J.R., Al-Zaidy S., Shell R., Arnold W.D., Rodino-Klapac L.R., Prior T.W., Lowes L., Alfano L., Berry K., Church K., et al.  Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N. Engl. J. Med. 2017;377:1713–1722. doi: 10.1056/NEJMoa1706198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1706198</ArticleId>
            <ArticleId IdType="pubmed">29091557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finkel R.S., Day J.W., Darras B.T., Kuntz N.L., Connolly A.M., Crawford T., Mendell J.R. One-Time Intrathecal (IT) Administration of AVXS-101 IT Gene-Replacement Therapy for Spinal Muscular Atrophy: Phase 1 Study (STRONG) (2493) Neurology. 2020;94((Suppl. 15)):2493.</Citation>
        </Reference>
        <Reference>
          <Citation>Strauss K., Farrar M., Muntoni F., Saito K., Mendell J., Servais L., McMillan H., Finkel R., Swoboda K., Kwon J., et al.  OPR-201 Onasemnogene abeparvovec for presymptomatic infants with spinal muscular atrophy and 2 copies of SMN2: A phase III study. Eur. J. Neurol. 2021;28((Suppl. S1)):S950–S951.</Citation>
        </Reference>
        <Reference>
          <Citation>Strauss K.A., Muntoni F., Farrar M.A., Saito K., Mendell J., Servais L., Macek T. Onasemnogene abeparvovec gene therapy in presymptomatic spinal muscular atrophy (SMA): SPR1NT study update in children with 3 copies of SMN2 (4163) Neurology. 2021;96((Suppl. 15)):4163.</Citation>
        </Reference>
        <Reference>
          <Citation>Dangouloff T., Vrščaj E., Servais L., Osredkar D., Adoukonou T., Aryani O., Barisic N., Bashiri F., Bastaki L., Benitto A., et al.  Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go. Neuromuscul. Disord. 2021;31:574–582. doi: 10.1016/j.nmd.2021.03.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2021.03.007</ArticleId>
            <ArticleId IdType="pubmed">33985857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kashima T., Manley J.L. A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat. Genet. 2003;34:460–463. doi: 10.1038/ng1207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng1207</ArticleId>
            <ArticleId IdType="pubmed">12833158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cartegni L., Krainer A.R. Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat. Genet. 2002;30:377–384. doi: 10.1038/ng854.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng854</ArticleId>
            <ArticleId IdType="pubmed">11925564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiriboga C.A., Swoboda K.J., Darras B.T., Iannaccone S.T., Montes J., De Vivo D.C., Norris D.A., Bennett C.F., Bishop K.M. Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy. Neurology. 2016;86:890–897. doi: 10.1212/WNL.0000000000002445.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000002445</ArticleId>
            <ArticleId IdType="pmc">PMC4782111</ArticleId>
            <ArticleId IdType="pubmed">26865511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haché M., Swoboda K.J., Sethna N., Farrow-Gillespie A., Khandji A., Xia S., Bishop K.M. Intrathecal Injections in Children With Spinal Muscular Atrophy. J. Child Neurol. 2016;31:899–906. doi: 10.1177/0883073815627882.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0883073815627882</ArticleId>
            <ArticleId IdType="pmc">PMC4871174</ArticleId>
            <ArticleId IdType="pubmed">26823478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finkel R.S., Chiriboga C.A., Vajsar J., Day J.W., Montes J., De Vivo D.C., Yamashita M., Rigo F., Hung G., Schneider E., et al.  Treatment of infantile-onset spinal muscular atrophy with nusinersen: A phase 2, open-label, dose-escalation study. Lancet. 2016;388:3017–3026. doi: 10.1016/S0140-6736(16)31408-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(16)31408-8</ArticleId>
            <ArticleId IdType="pubmed">27939059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finkel R.S., Mercuri E., Darras B.T., Connolly A.M., Kuntz N.L., Kirschner J., Chiriboga C.A., Saito K., Servais L., Tizzano E., et al.  Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N. Engl. J. Med. 2017;377:1723–1732. doi: 10.1056/NEJMoa1702752.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1702752</ArticleId>
            <ArticleId IdType="pubmed">29091570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mercuri E., Darras B.T., Chiriboga C.A., Day J.W., Campbell C., Connolly A.M., Iannaccone S.T., Kirschner J., Kuntz N.L., Saito K., et al.  Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. N. Engl. J. Med. 2018;378:625–635. doi: 10.1056/NEJMoa1710504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1710504</ArticleId>
            <ArticleId IdType="pubmed">29443664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>U.S. Food and Drug Administration   [(accessed on 27 March 2022)]; Available online:  https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-spinal-muscular-atrophy.</Citation>
        </Reference>
        <Reference>
          <Citation>Darras B.T., Farrar M.A., Mercuri E., Finkel R.S., Foster R., Hughes S.G., Bhan I., Farwell W., Gheuens S. An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials. CNS Drugs. 2019;33:919–932. doi: 10.1007/s40263-019-00656-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40263-019-00656-w</ArticleId>
            <ArticleId IdType="pmc">PMC6776494</ArticleId>
            <ArticleId IdType="pubmed">31420846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duan D. Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy. Mol. Ther. 2018;26:2337–2356. doi: 10.1016/j.ymthe.2018.07.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ymthe.2018.07.011</ArticleId>
            <ArticleId IdType="pmc">PMC6171037</ArticleId>
            <ArticleId IdType="pubmed">30093306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoffman E.P., Brown R.H., Jr., Kunkel L.M. Dystrophin: The protein product of the duchenne muscular dystrophy locus. Cell. 1987;51:919–928. doi: 10.1016/0092-8674(87)90579-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0092-8674(87)90579-4</ArticleId>
            <ArticleId IdType="pubmed">3319190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Passamano L., Taglia A., Palladino A., Viggiano E., D’Ambrosio P., Scutifero M., Cecio M.R., Torre V., De Luca F., Picillo E., et al.  Improvement of survival in Duchenne Muscular Dystrophy: Retrospective analysis of 835 patients. Acta Myol. 2012;31:121–125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3476854</ArticleId>
            <ArticleId IdType="pubmed">23097603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Monaco A.P., Bertelson C.J., Liechti-Gallati S., Moser H., Kunkel L.M. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics. 1988;2:90–95. doi: 10.1016/0888-7543(88)90113-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0888-7543(88)90113-9</ArticleId>
            <ArticleId IdType="pubmed">3384440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pfizer   [(accessed on 27 March 2022)].  Available online:  https://www.pfizer.com/news/press-release/press-release-detail/pfizers-new-phase-1b-results-gene-therapy-ambulatory-boys.</Citation>
        </Reference>
        <Reference>
          <Citation>Crudele J.M., Chamberlain J.S. AAV-based gene therapies for the muscular dystrophies. Hum. Mol. Genet. 2019;28:R102–R107. doi: 10.1093/hmg/ddz128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddz128</ArticleId>
            <ArticleId IdType="pmc">PMC6796995</ArticleId>
            <ArticleId IdType="pubmed">31238336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Charleston J.S., Schnell F.J., Dworzak J., Donoghue C., Lewis S., Chen L., Young G.D., Milici A.J., Voss J., Dealwis U., et al.  Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production. Neurology. 2018;90:e2146–e2154. doi: 10.1212/WNL.0000000000005680.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000005680</ArticleId>
            <ArticleId IdType="pubmed">29752304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cirak S., Arechavala-Gomeza V., Guglieri M., Feng L., Torelli S., Anthony K., Abbs S., Garralda M.E., Bourke J., Wells D.J., et al.  Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study. Lancet. 2011;378:595–605. doi: 10.1016/S0140-6736(11)60756-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(11)60756-3</ArticleId>
            <ArticleId IdType="pmc">PMC3156980</ArticleId>
            <ArticleId IdType="pubmed">21784508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mendell J.R., Rodino-Klapac L.R., Sahenk Z., Roush K., Bird L., Lowes L.P., Alfano L., Gomez A.M., Lewis S., Kota J., et al.  Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann. Neurol. 2013;74:637–647. doi: 10.1002/ana.23982.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.23982</ArticleId>
            <ArticleId IdType="pubmed">23907995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kesselheim A., Avorn J. Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy. JAMA. 2016;316:2357–2358. doi: 10.1001/jama.2016.16437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2016.16437</ArticleId>
            <ArticleId IdType="pubmed">27775756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mendell J.R., Goemans N., Lowes L.P., Alfano L.N., Berry K., Shao J., Kaye E.M., Mercuri E., Eteplirsen Study Group and Telethon Foundation DMD Italian Network  Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann. Neurol. 2016;79:257–271. doi: 10.1002/ana.24555.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.24555</ArticleId>
            <ArticleId IdType="pmc">PMC5064753</ArticleId>
            <ArticleId IdType="pubmed">26573217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frank D.E., Schnell F.J., Akana C., El-Husayni S.H., Desjardins C.A., Morgan J., Charleston J.S., Sardone V., Domingos J., Dickson G., et al.  Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology. 2020;94:e2270–e2282. doi: 10.1212/WNL.0000000000009233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000009233</ArticleId>
            <ArticleId IdType="pmc">PMC7357297</ArticleId>
            <ArticleId IdType="pubmed">32139505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clemens P.R., Rao V.K., Connolly A.M., Harper A.D., Mah J.K., Smith E.C., McDonald C.M., Zaidman C.M., Morgenroth L.P., Osaki H., et al.  Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial. JAMA Neurol. 2020;77:982–991. doi: 10.1001/jamaneurol.2020.1264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2020.1264</ArticleId>
            <ArticleId IdType="pmc">PMC7251505</ArticleId>
            <ArticleId IdType="pubmed">32453377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Komaki H., Takeshima Y., Matsumura T., Ozasa S., Funato M., Egawa Y., Takeda S. DMD CLINICAL THERAPIES II: P. 129A Japanese phase I/II study of NS-065/NCNP-01, exon 53 skipping drug, in patients with Duchenne muscular dystrophy—A dose-finding study. Neuromuscul. Disord. 2018;28:S68. doi: 10.1016/j.nmd.2018.06.157.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2018.06.157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>U.S. Food and Drug Administration   [(accessed on 27 March 2022)]; Available online:  https://www.fda.gov/news-events/press-announcements/fda-approves-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation.</Citation>
        </Reference>
        <Reference>
          <Citation>NS Pharma   [(accessed on 27 March 2022)].  Available online:  https://www.nspharma.com/pdfs/NSPharma_Long-term_Data_PPMD_New.pdf.</Citation>
        </Reference>
        <Reference>
          <Citation>Amantana A., Iversen P.L. Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers. Curr. Opin. Pharmacol. 2005;5:550–555. doi: 10.1016/j.coph.2005.07.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.coph.2005.07.001</ArticleId>
            <ArticleId IdType="pubmed">16087398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gebski B.L., Mann C.J., Fletcher S., Wilton S.D. Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum. Mol. Genet. 2003;12:1801–1811. doi: 10.1093/hmg/ddg196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddg196</ArticleId>
            <ArticleId IdType="pubmed">12874101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Richard J.-P., Melikov K., Vives E., Ramos C., Verbeure B., Gait M.J., Chernomordik L.V., Lebleu B. Cell-penetrating Peptides: A reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 2003;278:585–590. doi: 10.1074/jbc.M209548200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M209548200</ArticleId>
            <ArticleId IdType="pubmed">12411431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gait M.J., Arzumanov A.A., McClorey G., Godfrey C., Betts C., Hammond S., Wood M.J. Cell-Penetrating Peptide Conjugates of Steric Blocking Oligonucleotides as Therapeutics for Neuromuscular Diseases from a Historical Perspective to Current Prospects of Treatment. Nucleic Acid Ther. 2019;29:1–12. doi: 10.1089/nat.2018.0747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/nat.2018.0747</ArticleId>
            <ArticleId IdType="pmc">PMC6386087</ArticleId>
            <ArticleId IdType="pubmed">30307373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarepta Therapeutics.  [(accessed on 27 March 2022)].  Available online:  https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-positive-clinical-results.</Citation>
        </Reference>
        <Reference>
          <Citation>Ito K., Takakusa H., Kakuta M., Kanda A., Takagi N., Nagase H., Watanabe N., Asano D., Goda R., Masuda T., et al.  Renadirsen, a Novel 2′OMeRNA/ENA® Chimera Antisense Oligonucleotide, Induces Robust Exon 45 Skipping for Dystrophin In Vivo. Curr. Issues Mol. Biol. 2021;43:1267–1281. doi: 10.3390/cimb43030090.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cimb43030090</ArticleId>
            <ArticleId IdType="pmc">PMC8928966</ArticleId>
            <ArticleId IdType="pubmed">34698059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daiichi Sankyo   [(accessed on 27 March 2022)].  Available online:  https://www.daiichisankyo.com/media/press_release/detail/index_4112.html.</Citation>
        </Reference>
        <Reference>
          <Citation>Wagner K., Phan H., Servais L., Gidaro T., Cripe L., Eagle M., Muntoni F., Straub V., Lonkar P., Schmitz S., et al.  O.28Safety and tolerability of suvodirsen (WVE-210201) in patients with Duchenne muscular dystrophy: Results from a phase 1 clinical trial. Neuromuscul. Disord. 2019;29:S124. doi: 10.1016/j.nmd.2019.06.311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2019.06.311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wave Life Sciences   [(accessed on 27 March 2022)].  Available online:  https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-announces-discontinuation-suvodirsen.</Citation>
        </Reference>
        <Reference>
          <Citation>Wave Life Sciences   [(accessed on 27 March 2022)].  Available online:  https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-announces-initiation-dosing-phase-1b2a.</Citation>
        </Reference>
        <Reference>
          <Citation>Gadgil A., Raczyńska K.D. U7 snRNA: A tool for gene therapy. J. Gene Med. 2021;23:e3321. doi: 10.1002/jgm.3321.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jgm.3321</ArticleId>
            <ArticleId IdType="pmc">PMC8243935</ArticleId>
            <ArticleId IdType="pubmed">33590603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walton J.N., Nattrass F.J. On the classification, natural history and treatment of the myopathies. Brain. 1954;77:169–231. doi: 10.1093/brain/77.2.169.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/77.2.169</ArticleId>
            <ArticleId IdType="pubmed">13190076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bushby K.M.D.  Limb-girdle muscular dystrophy. In: Emery A.E.H., editor. Diagnostic Criteria for Neuromuscular Disorders. ENMC; Baarn, The Netherlands: 1994. pp. 25–31.</Citation>
        </Reference>
        <Reference>
          <Citation>Bushby K., Muntoni F., Bourke J.P. 107th ENMC International Workshop: The management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th–9th June 2002, Naarden, the Netherlands. Neuromuscul. Disord. 2003;13:166–172. doi: 10.1016/S0960-8966(02)00213-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0960-8966(02)00213-4</ArticleId>
            <ArticleId IdType="pubmed">12565916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kirschner J., Bönnemann C.G. The congenital and limb-girdle muscular dystrophies: Sharpening the focus, blurring the boundaries. Arch. Neurol. 2004;61:189–199. doi: 10.1001/archneur.61.2.189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.61.2.189</ArticleId>
            <ArticleId IdType="pubmed">14967765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Minetti C., Sotgia F., Bruno C., Scartezzini P., Broda P., Bado M., Masetti E., Mazzocco M., Egeo A., Donati M.A., et al.  Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat. Genet. 1998;18:365–368. doi: 10.1038/ng0498-365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng0498-365</ArticleId>
            <ArticleId IdType="pubmed">9537420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Narayanaswami P., Weiss M., Selcen D., David W., Raynor E., Carter G., Wicklund M., Barohn R.J., Ensrud E., Griggs R., et al.  Evidence-based guideline summary: Diagnosis and treatment of limb-girdle and distal dystrophies: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular &amp; Electrodiagnostic Medicine. Neurology. 2014;83:1453–1463. doi: 10.1212/wnl.0000000000000892.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/wnl.0000000000000892</ArticleId>
            <ArticleId IdType="pmc">PMC4206155</ArticleId>
            <ArticleId IdType="pubmed">25313375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wicklund M.P., Kissel J.T. The Limb-Girdle Muscular Dystrophies. Neurol. Clin. 2014;32:729–749. doi: 10.1016/j.ncl.2014.04.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ncl.2014.04.005</ArticleId>
            <ArticleId IdType="pubmed">25037088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iyadurai S.J.P., Kissel J.T. The Limb-Girdle Muscular Dystrophies and the Dystrophinopathies. Contin. Lifelong Learn. Neurol. 2016;22:1954–1977. doi: 10.1212/CON.0000000000000406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/CON.0000000000000406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liewluck T., Milone M. Untangling the complexity of limb-girdle muscular dystrophies. Muscle Nerve. 2018;58:167–177. doi: 10.1002/mus.26077.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.26077</ArticleId>
            <ArticleId IdType="pubmed">29350766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Straub V., Murphy A., Udd B., LGMD Workshop Study Group  229th ENMC international workshop: Limb girdle muscular dystrophies—Nomenclature and reformed classification Naarden, the Netherlands, 17–19 March 2017. Neuromuscul. Disord. 2018;28:702–710. doi: 10.1016/j.nmd.2018.05.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2018.05.007</ArticleId>
            <ArticleId IdType="pubmed">30055862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu W., Pajusalu S., Lake N.J., Zhou G., Ioannidis N., Mittal P., Johnson N.E., Weihl C.C., Williams B.A., Albrecht D.E., et al.  Estimating prevalence for limb-girdle muscular dystrophy based on public sequencing databases. Genet. Med. 2019;21:2512–2520. doi: 10.1038/s41436-019-0544-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41436-019-0544-8</ArticleId>
            <ArticleId IdType="pubmed">31105274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bashir R., Britton S., Strachan T., Keers S., Vafiadaki E., Lako M., Richard I., Marchand S., Bourg N., Argov Z., et al.  A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat. Genet. 1998;20:37–42. doi: 10.1038/1689.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/1689</ArticleId>
            <ArticleId IdType="pubmed">9731527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J., Aoki M., Illa I., Wu C., Fardeau M., Angelini C., Serrano C., Urtizberea J.A., Hentati F., Ben Hamida M., et al.  Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat. Genet. 1998;20:31–36. doi: 10.1038/1682.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/1682</ArticleId>
            <ArticleId IdType="pubmed">9731526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Illa I., Serrano-Munuera C., Gallardo E., Lasa A., Rojas-García R., Palmer J., Gallano P., Baiget M., Matsuda C., Brown R.H. Distal anterior compartment myopathy: A dysferlin mutation causing a new muscular dystrophy phenotype. Ann. Neurol. 2001;49:130–134. doi: 10.1002/1531-8249(200101)49:1&lt;130::AID-ANA22&gt;3.0.CO;2-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1531-8249(200101)49:1&lt;130::AID-ANA22&gt;3.0.CO;2-0</ArticleId>
            <ArticleId IdType="pubmed">11198284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paradas C., Llauger J., Diaz-Manera J., Rojas-Garcia R., De Luna N., Iturriaga C., Marquez C., Uson M., Hankiewicz K., Gallardo E., et al.  Redefining dysferlinopathy phenotypes based on clinical findings and muscle imaging studies. Neurology. 2010;75:316–323. doi: 10.1212/WNL.0b013e3181ea1564.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e3181ea1564</ArticleId>
            <ArticleId IdType="pubmed">20574037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen K., Bassez G., Krahn M., Bernard R., Laforêt P., Labelle V., Urtizberea J.A., Figarella-Branger D., Romero N., Attarian S., et al.  Phenotypic study in 40 patients with dysferlin gene mutations: High frequency of atypical phenotypes. Arch. Neurol. 2007;64:1176–1182. doi: 10.1001/archneur.64.8.1176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.64.8.1176</ArticleId>
            <ArticleId IdType="pubmed">17698709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ueyama H., Kumamoto T., Horinouchi H., Fujimoto S., Aono H., Tsuda T. Clinical Heterogeneity in Dysferlinopathy. Intern. Med. 2002;41:532–536. doi: 10.2169/internalmedicine.41.532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2169/internalmedicine.41.532</ArticleId>
            <ArticleId IdType="pubmed">12132520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pozsgai E., Griffin D., Potter R., Sahenk Z., Lehman K., Rodino-Klapac L.R., Mendell J.R. Unmet needs and evolving treatment for limb girdle muscular dystrophies. Neurodegener. Dis. Manag. 2021;11:411–429. doi: 10.2217/nmt-2020-0066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/nmt-2020-0066</ArticleId>
            <ArticleId IdType="pubmed">34472379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiler T., Bashir R., Anderson L.V.B., Davison K., Moss J.A., Britton S., Nylen E., Keers S., Vafiadaki E., Greenberg C.R., et al.  Identical Mutation in Patients with Limb Girdle Muscular Dystrophy Type 2B Or Miyoshi Myopathy Suggests a Role for Modifier Gene(s) Hum. Mol. Genet. 1999;8:871–877. doi: 10.1093/hmg/8.5.871.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/8.5.871</ArticleId>
            <ArticleId IdType="pubmed">10196377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ueyama H., Kumamoto T., Nagao S.-I., Masuda T., Horinouchi H., Fujimoto S., Tsuda T. A new dysferlin gene mutation in two Japanese families with limb-girdle muscular dystrophy 2B and Miyoshi myopathy. Neuromuscul. Disord. 2001;11:139–145. doi: 10.1016/S0960-8966(00)00168-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0960-8966(00)00168-1</ArticleId>
            <ArticleId IdType="pubmed">11257469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cacciottolo M., Numitone G., Aurino S., Caserta I.R., Fanin M., Politano L., Minetti C., Ricci E., Piluso G., Angelini C., et al.  Muscular dystrophy with marked Dysferlin deficiency is consistently caused by primary dysferlin gene mutations. Eur. J. Hum. Genet. 2011;19:974–980. doi: 10.1038/ejhg.2011.70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ejhg.2011.70</ArticleId>
            <ArticleId IdType="pmc">PMC3179367</ArticleId>
            <ArticleId IdType="pubmed">21522182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sondergaard P.C., Griffin D.A., Pozsgai E.R., Johnson R.W., Grose W.E., Heller K.N., Shontz K.M., Montgomery C.L., Liu J., Clark K.R., et al.  AAV. Dysferlin Overlap Vectors Restore Function in Dysferlinopathy Animal Models. Ann. Clin. Transl. Neurol. 2015;2:256–270. doi: 10.1002/acn3.172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acn3.172</ArticleId>
            <ArticleId IdType="pmc">PMC4369275</ArticleId>
            <ArticleId IdType="pubmed">25815352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Potter R.A., Griffin D.A., Sondergaard P.C., Johnson R.W., Pozsgai E.R., Heller K.N., Peterson E.L., Lehtimäki K.K., Windish H.P., Mittal P.J., et al.  Systemic Delivery of Dysferlin Overlap Vectors Provides Long-Term Gene Expression and Functional Improvement for Dysferlinopathy. Hum. Gene Ther. 2018;29:749–762. doi: 10.1089/hum.2017.062.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/hum.2017.062</ArticleId>
            <ArticleId IdType="pmc">PMC6066196</ArticleId>
            <ArticleId IdType="pubmed">28707952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim L.E., Duclos F., Broux O., Bourg N., Sunada Y., Allamand V., Meyer J., Richard I., Moomaw C., Slaughter C., et al.  β–sarcoglycan: Characterization and role in limb–girdle muscular dystrophy linked to 4q12. Nat. Genet. 1995;11:257–265. doi: 10.1038/ng1195-257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng1195-257</ArticleId>
            <ArticleId IdType="pubmed">7581448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noguchi S., McNally E.M., Ben Othmane K., Hagiwara Y., Mizuno Y., Yoshida M., Yamamoto H., Bönnemann C.G., Gussoni E., Denton P.H., et al.  Mutations in the Dystrophin-Associated Protein γ-Sarcoglycan in Chromosome 13 Muscular Dystrophy. Science. 1995;270:819–822. doi: 10.1126/science.270.5237.819.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.270.5237.819</ArticleId>
            <ArticleId IdType="pubmed">7481775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duggan D.J., Gorospe J.R., Fanin M., Hoffman E.P., Angelini C., Pegoraro E., Noguchi S., Ozawa E., Pendlebury W., Waclawik A., et al.  Mutations in the Sarcoglycan Genes in Patients with Myopathy. N. Engl. J. Med. 1997;336:618–625. doi: 10.1056/NEJM199702273360904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM199702273360904</ArticleId>
            <ArticleId IdType="pubmed">9032047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vainzof M., Souza L.S., Gurgel-Giannetti J., Zatz M. Sarcoglycanopathies: An update. Neuromuscul. Disord. 2021;31:1021–1027. doi: 10.1016/j.nmd.2021.07.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2021.07.014</ArticleId>
            <ArticleId IdType="pubmed">34404573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herson S., Hentati F., Rigolet A., Behin A., Romero N.B., Leturcq F., Laforêt P., Maisonobe T., Amouri R., Haddad H., et al.  A phase I trial of adeno-associated virus serotype 1-γ-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C. Brain. 2012;135:483–492. doi: 10.1093/brain/awr342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awr342</ArticleId>
            <ArticleId IdType="pubmed">22240777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nigro V., Savarese M. Genetic basis of limb-girdle muscular dystrophies: The 2014 update. Acta Myol. 2014;33:1–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4021627</ArticleId>
            <ArticleId IdType="pubmed">24843229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mendell J.R., Rodino-Klapac L.R., Rosales-Quintero X., Kota J., Coley B., Galloway G., Craenen J.M., Lewis S., Malik V., Ms C.S., et al.  Limb-girdle muscular dystrophy type 2D gene therapy restores α-sarcoglycan and associated proteins. Ann. Neurol. 2009;66:290–297. doi: 10.1002/ana.21732.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.21732</ArticleId>
            <ArticleId IdType="pmc">PMC6014624</ArticleId>
            <ArticleId IdType="pubmed">19798725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mendell J.R., Rodino-Klapac L.R., Rosales X.Q., Coley B., Galloway G., Lewis S.L., Malik V., Shilling C., Byrne B.J., Conlon T.J., et al.  Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann. Neurol. 2010;68:629–638. doi: 10.1002/ana.22251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.22251</ArticleId>
            <ArticleId IdType="pmc">PMC2970162</ArticleId>
            <ArticleId IdType="pubmed">21031578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mendell J.R., Sahenk Z., Lehman K., Nease C., Lowes L.P., Miller N.F., Iammarino M.A., Alfano L.N., Nicholl A., Al-Zaidy S., et al.  Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial. JAMA Neurol. 2020;77:1122–1131. doi: 10.1001/jamaneurol.2020.1484.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2020.1484</ArticleId>
            <ArticleId IdType="pmc">PMC7296461</ArticleId>
            <ArticleId IdType="pubmed">32539076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mendell J.R., Chicoine L.G., Al-Zaidy S.A., Sahenk Z., Lehman K., Lowes L., Miller N., Alfano L., Galliers B., Lewis S., et al.  Gene Delivery for Limb-Girdle Muscular Dystrophy Type 2D by Isolated Limb Infusion. Hum. Gene Ther. 2019;30:794–801. doi: 10.1089/hum.2019.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/hum.2019.006</ArticleId>
            <ArticleId IdType="pmc">PMC6648191</ArticleId>
            <ArticleId IdType="pubmed">30838895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bönnemann C.G., Passos-Bueno M.R., McNally E.M., Vainzof M., Moreira E.D.S., Marie S., Pavanello R.C.M., Noguchi S., Ozawa E., Zatz M., et al.  Genomic screening for beta-sarcoglycan gene mutations: Missense mutations may cause severe limb-girdle muscular dystrophy type 2E (LGMD 2E) Hum. Mol. Genet. 1996;5:1953–1961. doi: 10.1093/hmg/5.12.1953.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/5.12.1953</ArticleId>
            <ArticleId IdType="pubmed">8968749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Semplicini C., Vissing J., Dahlqvist J.R., Stojkovic T., Bello L., Witting N., Duno M., Leturcq F., Bertolin C., D’Ambrosio P., et al.  Clinical and genetic spectrum in limb-girdle muscular dystrophy type 2E. Neurology. 2015;84:1772–1781. doi: 10.1212/WNL.0000000000001519.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000001519</ArticleId>
            <ArticleId IdType="pmc">PMC4424130</ArticleId>
            <ArticleId IdType="pubmed">25862795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pozsgai E.R., Griffin D.A., Heller K.N., Mendell J.R., Rodino-Klapac L.R. Systemic AAV-Mediated β-Sarcoglycan Delivery Targeting Cardiac and Skeletal Muscle Ameliorates Histological and Functional Deficits in LGMD2E Mice. Mol. Ther. 2017;25:855–869. doi: 10.1016/j.ymthe.2017.02.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ymthe.2017.02.013</ArticleId>
            <ArticleId IdType="pmc">PMC5383645</ArticleId>
            <ArticleId IdType="pubmed">28284983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarepta Therapeutics   [(accessed on 27 March 2022)].  Available online:  https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-investigational-gene-therapy-srp-9003-0.</Citation>
        </Reference>
        <Reference>
          <Citation>Kanagawa M., Kobayashi K., Tajiri M., Manya H., Kuga A., Yamaguchi Y., Akasaka-Manya K., Furukawa J.-I., Mizuno M., Kawakami H., et al.  Identification of a Post-translational Modification with Ribitol-Phosphate and Its Defect in Muscular Dystrophy. Cell Rep. 2016;14:2209–2223. doi: 10.1016/j.celrep.2016.02.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2016.02.017</ArticleId>
            <ArticleId IdType="pubmed">26923585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mercuri E., Brockington M., Straub V., Quijano-Roy S., Yuva Y., Herrmann R., Brown S., Torelli S., Dubowitz V., Blake D.J., et al.  Phenotypic spectrum associated with mutations in the fukutin-related protein gene. Ann. Neurol. 2003;53:537–542. doi: 10.1002/ana.10559.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.10559</ArticleId>
            <ArticleId IdType="pubmed">12666124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brook J.D., McCurrach M.E., Harley H.G., Buckler A.J., Church D., Aburatani H., Hunter K., Stanton V.P., Thirion J.-P., Hudson T., et al.  Molecular basis of myotonic dystrophy: Expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell. 1992;68:799–808. doi: 10.1016/0092-8674(92)90154-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0092-8674(92)90154-5</ArticleId>
            <ArticleId IdType="pubmed">1310900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harley H.G., Brook J.D., Rundle S.A., Crow S., Reardon W., Buckler A.J., Harper P.S., Housman D.E., Shaw D.J. Expansion of an unstable DNA region and phenotypic variation in myotonic dystrophy. Nature. 1992;355:545–546. doi: 10.1038/355545a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/355545a0</ArticleId>
            <ArticleId IdType="pubmed">1346923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aslanidis C., Jansen G., Amemiya C., Shutler G., Mahadevan M., Tsilfidis C., Chen C., Alleman J., Wormskamp N.G.M., Vooijs M., et al.  Cloning of the essential myotonic dystrophy region and mapping of the putative defect. Nature. 1992;355:548–551. doi: 10.1038/355548a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/355548a0</ArticleId>
            <ArticleId IdType="pubmed">1346925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaliman P., Llagostera E. Myotonic dystrophy protein kinase (DMPK) and its role in the pathogenesis of myotonic dystrophy 1. Cell. Signal. 2008;20:1935–1941. doi: 10.1016/j.cellsig.2008.05.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellsig.2008.05.005</ArticleId>
            <ArticleId IdType="pubmed">18583094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho T.H., Charlet-B N., Poulos M.G., Singh G., Swanson M.S., Cooper T.A. Muscleblind proteins regulate al-ternative splicing. EMBO J. 2004;23:3103–3112. doi: 10.1038/sj.emboj.7600300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.emboj.7600300</ArticleId>
            <ArticleId IdType="pmc">PMC514918</ArticleId>
            <ArticleId IdType="pubmed">15257297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller J.W., Urbinati C.R., Teng-Umnuay P., Stenberg M.G., Byrne B.J., Thornton C.A., Swanson M.S. Recruitment of human muscleblind proteins to (CUG)n expansions associated with myotonic dystrophy. EMBO J. 2000;19:4439–4448. doi: 10.1093/emboj/19.17.4439.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/emboj/19.17.4439</ArticleId>
            <ArticleId IdType="pmc">PMC302046</ArticleId>
            <ArticleId IdType="pubmed">10970838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mulders S.A.M., van den Broek W.J., Wheeler T.M., Croes H.J.E., van Kuik-Romeijn P., de Kimpe S.J., Furling D., Platenburg G.J., Gourdon G., Thornton C.A., et al.  Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc. Natl. Acad. Sci. USA. 2009;106:13915–13920. doi: 10.1073/pnas.0905780106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0905780106</ArticleId>
            <ArticleId IdType="pmc">PMC2728995</ArticleId>
            <ArticleId IdType="pubmed">19667189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen Q., Yokota T. Degradation of Toxic RNA in Myotonic Dystrophy Using Gapmer Antisense Oligonucleotides. Methods Mol. Biol. 2020;2176:99–109. doi: 10.1007/978-1-0716-0771-8_7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-0716-0771-8_7</ArticleId>
            <ArticleId IdType="pubmed">32865785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang E.T., Cody N.A., Jog S., Biancolella M., Wang T.T., Treacy D.J., Luo S., Schroth G.P., Housman D.E., Reddy S., et al.  Transcriptome-wide Regulation of Pre-mRNA Splicing and mRNA Localization by Muscleblind Proteins. Cell. 2012;150:710–724. doi: 10.1016/j.cell.2012.06.041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.06.041</ArticleId>
            <ArticleId IdType="pmc">PMC3428802</ArticleId>
            <ArticleId IdType="pubmed">22901804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mankodi A., Takahashi M.P., Jiang H., Beck C.L., Bowers W.J., Moxley R.T., Cannon S., Thornton C.A. Expanded CUG Repeats Trigger Aberrant Splicing of ClC-1 Chloride Channel Pre-mRNA and Hyperexcitability of Skeletal Muscle in Myotonic Dystrophy. Mol. Cell. 2002;10:35–44. doi: 10.1016/S1097-2765(02)00563-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1097-2765(02)00563-4</ArticleId>
            <ArticleId IdType="pubmed">12150905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lueck J.D., Mankodi A., Swanson M.S., Thornton C.A., Dirksen R.T. Muscle Chloride Channel Dysfunction in Two Mouse Models of Myotonic Dystrophy. J. Gen. Physiol. 2007;129:79–94. doi: 10.1085/jgp.200609635.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1085/jgp.200609635</ArticleId>
            <ArticleId IdType="pmc">PMC2151606</ArticleId>
            <ArticleId IdType="pubmed">17158949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Savkur R.S., Philips A.V., Cooper T.A. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat. Genet. 2001;29:40–47. doi: 10.1038/ng704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng704</ArticleId>
            <ArticleId IdType="pubmed">11528389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meola G., Cardani R. Myotonic dystrophies: An update on clinical aspects, genetic, pathology, and molecular pathomechanisms. Biochim. Biophys. Acta. 2015;1852:594–606. doi: 10.1016/j.bbadis.2014.05.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbadis.2014.05.019</ArticleId>
            <ArticleId IdType="pubmed">24882752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zu T., Gibbens B., Doty N.S., Gomes-Pereira M., Huguet A., Stone M.D., Margolis J., Peterson M., Markowski T.W., Ingram M.A.C., et al.  Non-ATG–initiated translation directed by microsatellite expansions. Proc. Natl. Acad. Sci. USA. 2011;108:260–265. doi: 10.1073/pnas.1013343108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1013343108</ArticleId>
            <ArticleId IdType="pmc">PMC3017129</ArticleId>
            <ArticleId IdType="pubmed">21173221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thornton C.A. Myotonic dystrophy. Neurol. Clin. 2014;32:705–719. doi: 10.1016/j.ncl.2014.04.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ncl.2014.04.011</ArticleId>
            <ArticleId IdType="pmc">PMC4105852</ArticleId>
            <ArticleId IdType="pubmed">25037086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thornton C.A., Moxley R.T., Day J.W., Ashizawa T., Barohn R., Leung D., Kissel J., Johnson N., Eichinger K., Hardage J., et al.  Study Design of a Phase 1/2a Trial with ISIS-DMPKRx for the Treatment of Myotonic Dystrophy Type 1 (P3.167) Neurology. 2016;86((Suppl. 16)):P3.167.</Citation>
        </Reference>
        <Reference>
          <Citation>Mignon L., Norris D., Bishop K., Derosier F., LANE R., Bennett F. ISIS-DMPKRx in Healthy Volunteers: A Placebo-controlled, Randomized, Single Ascending-Dose Phase 1 Study (P3.166) Neurology. 2016;86((Suppl. 16)):P3.166.</Citation>
        </Reference>
        <Reference>
          <Citation>Hu N., Antoury L., Baran T.M., Mitra S., Bennett C.F., Rigo F., Foster T., Wheeler T.M. Non-invasive monitoring of alternative splicing outcomes to identify candidate therapies for myotonic dystrophy type 1. Nat. Commun. 2018;9:5227. doi: 10.1038/s41467-018-07517-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-018-07517-y</ArticleId>
            <ArticleId IdType="pmc">PMC6286378</ArticleId>
            <ArticleId IdType="pubmed">30531949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Avidity Biosciences   [(accessed on 27 March 2022)].  Available online:  https://aviditybiosciences.investorroom.com/2021-08-02-Avidity-Biosciences-Receives-IND-Clearance-from-FDA-to-Proceed-with-the-Phase-1-2-MARINA-TM-Trial-of-AOC-1001-in-Adults-with-Myotonic-Dystrophy-DM1]</Citation>
        </Reference>
        <Reference>
          <Citation>Avidity Biosciences   [(accessed on 27 March 2022)].  Available online:  https://aviditybiosciences.investorroom.com/2021-11-04-Avidity-Announces-First-Person-Dosed-with-an-Antibody-Oligonucleotide-Conjugate-AOC-TM.</Citation>
        </Reference>
        <Reference>
          <Citation>Brenner D., Ludolph A.C., Weishaupt J.H. Gene specific therapies—The next therapeutic milestone in neurology. Neurol. Res. Pract. 2020;2:25. doi: 10.1186/s42466-020-00075-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s42466-020-00075-z</ArticleId>
            <ArticleId IdType="pmc">PMC7650126</ArticleId>
            <ArticleId IdType="pubmed">33324928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hinderer C., Katz N., Buza E.L., Dyer C., Goode T., Bell P., Richman L.K., Wilson J. Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum. Gene Ther. 2018;29:285–298. doi: 10.1089/hum.2018.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/hum.2018.015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hordeaux J., Buza E.L., Dyer C., Goode T., Mitchell T.W., Richman L., Denton N., Hinderer C., Katz N., Schmid R., et al.  Adeno-Associated Virus-Induced Dorsal Root Ganglion Pathology. Hum. Gene Ther. 2020;31:808–818. doi: 10.1089/hum.2020.167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/hum.2020.167</ArticleId>
            <ArticleId IdType="pubmed">32845779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang X., Yang Y. Innate Immune Recognition of Viruses and Viral Vectors. Hum. Gene Ther. 2009;20:293–301. doi: 10.1089/hum.2008.141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/hum.2008.141</ArticleId>
            <ArticleId IdType="pmc">PMC2858295</ArticleId>
            <ArticleId IdType="pubmed">19272012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chandler R.J., Sands M.S., Venditti C.P. Recombinant Adeno-Associated Viral Integration and Genotoxicity: Insights from Animal Models. Hum. Gene Ther. 2017;28:314–322. doi: 10.1089/hum.2017.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/hum.2017.009</ArticleId>
            <ArticleId IdType="pmc">PMC5399742</ArticleId>
            <ArticleId IdType="pubmed">28293963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scoto M., Finkel R., Mercuri E., Muntoni F. Genetic therapies for inherited neuromuscular disorders. Lancet Child Adolesc. Health. 2018;2:600–609. doi: 10.1016/S2352-4642(18)30140-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2352-4642(18)30140-8</ArticleId>
            <ArticleId IdType="pubmed">30119719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manno C.S., Pierce G.F., Arruda V.R., Glader B., Ragni M., Rasko J.J., Ozelo M.C., Hoots K., Blatt P., Konkle B., et al.  Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 2006;12:342–347. doi: 10.1038/nm1358. Erratum in Nat. Med.
2006, 12, 592.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm1358</ArticleId>
            <ArticleId IdType="pubmed">16474400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Louis Jeune V., Joergensen J.A., Hajjar R.J., Weber T. Pre-existing Anti–Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy. Hum. Gene Ther. Methods. 2013;24:59–67. doi: 10.1089/hgtb.2012.243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/hgtb.2012.243</ArticleId>
            <ArticleId IdType="pmc">PMC3732124</ArticleId>
            <ArticleId IdType="pubmed">23442094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samaranch L., Salegio E.A., San Sebastian W., Kells A.P., Foust K.D., Bringas J.R., Lamarre C., Forsayeth J., Kaspar B.K., Bankiewicz K.S. Adeno-Associated Virus Serotype 9 Transduction in the Central Nervous System of Nonhuman Primates. Hum. Gene Ther. 2012;23:382–389. doi: 10.1089/hum.2011.200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/hum.2011.200</ArticleId>
            <ArticleId IdType="pmc">PMC3327605</ArticleId>
            <ArticleId IdType="pubmed">22201473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gray S.J., Nagabhushan Kalburgi S., McCown T.J., Jude Samulski R. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther. 2013;20:450–459. doi: 10.1038/gt.2012.101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/gt.2012.101</ArticleId>
            <ArticleId IdType="pmc">PMC3618620</ArticleId>
            <ArticleId IdType="pubmed">23303281</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
